Showing 1 - 9 results of 9 for search 'Melek Karakurt Eryılmaz', query time: 0.05s
Refine Results
-
1
-
2
Lymph Node Ratio Predictive of Survival in Node-Positive Head and Neck Cancer by Mustafa KORKMAZ, Melek KARAKURT ERYILMAZ, Mustafa KARAAĞAÇ, Mehmet ARTAÇ
Published 2022-04-01
Article -
3
-
4
-
5
A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer by Mehmet Zahid Kocak, Murat Araz, Siddika Findik, Aykut Demirkiran, Mustafa Korkmaz, Melek Karakurt Eryilmaz, Mehmet Artac
Published 2025-01-01
Article -
6
ERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung cancer by Mustafa Karaagac, Mehmet Artac, Caglayan Geredeli, Melek Karakurt Eryilmaz, Mahmut Selman Yildirim, Tuba Akkuloglu, Ali Inal, Abdurrahman Isikdogan, Hakan Bozcuk, Ahmet Demirkazik
Published 2020-03-01
Article -
7
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer by Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt
Published 2024-01-01
Article -
8
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer by Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt
Published 2024-01-01
Article -
9
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study by Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aydın, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gülhan Dinç, Ali Aytaç, Ziya Kalkan, Senar Ebinç, İlkay Gültürk, Merve Keskinkılıç, Zehra Sucuoğlu İşleyen, Dilek Çağlayan, Alper Türkel, Esra Aydın, Teoman Şakalar, Serhat Sekmek, Nilgün Yıldırım, Sinem Koçak, Kerem Okutur, Ahmet Özveren, Bengü Dursun, Sait Kitaplı, Orhan Önder Eren, İsmail Beypınar, İlhan Hacıbekiroğlu, Devrim Çabuk, Elanur Karaman, Ömer Acar, Semra Paydaş, Melek Karakurt Eryılmaz, Bilgin Demir, Zeynep Oruç, Mesut Yılmaz, Fatih Selçuk Biricik, Derya Kıvrak Salim, Özgür Tanrıverdi, Mutlu Doğan
Published 2024-10-01
Article